01.12.2015 | Research article | Ausgabe 1/2015 Open Access

The clinical features of respiratory infections caused by the Streptococcus anginosus group
- Zeitschrift:
- BMC Pulmonary Medicine > Ausgabe 1/2015
Electronic supplementary material
Competing interests
Authors’ contributions
Background
Methods
Study design and patients
Diagnostic criteria
Microbiological evaluation
Statistical analysis
Results
Patient characteristics and laboratory findings of 30 patients
Total (
n = 30)
|
|
---|---|
Age (y); mean ± SD
|
68.9 ± 14.2
|
Gender (male/female)
|
22/8
|
BMI; mean ± SD
|
20.1 ± 4.1
|
Comorbidity diseases
|
28 (93.3)
|
Neoplastic disease
|
8 (26.7)
|
Cerebrovascular disease
|
12 (40.0)
|
Chronic pulmonary disease
|
3 (10.0)
|
Chronic cardiac disease
|
4 (13.3)
|
Chronic liver disease
|
3 (10.0)
|
Chronic renal disease
|
4 (13.3)
|
Diabetes mellitus
|
6 (20.0)
|
Smoking history
|
13 (43.3)
|
Alcohol
|
8 (26.7)
|
The days from symptom onset to consultation (days)
|
15.1 ± 18.1
|
Symptoms at presentation
|
|
Fever
|
24 (80.0)
|
Cough
|
14 (46.7)
|
Sputum
|
14 (46.7)
|
Blood sputum
|
2 (6.7)
|
Chest pain
|
14 (46.7)
|
Disturbance of consciousness
|
3 (10.0)
|
Previous antibiotic treatment
|
8 (26.7)
|
Clinical parameter
|
|
Body temperature (°C)
|
37.8 ± 0.7
|
Systolic blood pressure (mmHg)
|
118.8 ± 20.9
|
Heart rate (beats/min)
|
103.7 ± 17.0
|
Respiratory rate (/min)
|
23.3 ± 5.7
|
Hypoxia (SpO
2 ≤ 90 %)
|
18 (60.0)
|
Laboratory findings
|
|
White blood cell counts (/μL)
|
17,627 ± 10,008
|
C-reactive protein (mg/dL)
|
18.0 ± 11.1
|
Albumin (g/dL)
|
2.5 ± 0.6
|
Pleural effusion
|
22 (73.3)
|
Complicated pleural effusion
|
10 (33.3)
|
Empyema
|
11 (36.7)
|
Cultured bacteria
|
|
SAG only
|
24 (80.0)
|
Mixed infection
|
6 (20.0)
|
Pneumonia severity index
|
120.8 ± 42.2
|
Antibiotic treatment
|
|
Monotherapy
|
25 (83.3)
|
Penicillin/beta-lactamase inhibitors
|
3 (10.0)
|
Carbapenem
|
19 (63.3)
|
Linezolid
|
1 (3.3)
|
Macrolide
|
2 (6.7)
|
Combination therapy
|
5 (16.7)
|
3th-cephem + Macrolide
|
1 (3.3)
|
4th-cephem + Clindamycin
|
1 (3.3)
|
Carbapenem + Clindamycin
|
2 (6.7)
|
Fluoroquinolone + Clindamycin
|
1 (3.3)
|
Additional treatment
|
|
Only drainage
|
5 (16.7)
|
Drainage + lung decortication
|
14 (46.7)
|
Length of stay (days)
|
27.7 ± 18.8
|
ICU admission
|
6 (20.0)
|
In-hospital mortality
|
2 (6.7)
|
Clinical outcomes
Microbiology
Cultured bacteria
|
No (%)
|
---|---|
S. intermedius
|
16 (53.3)
|
S. intermedius only
|
14 (46.7)
|
S. intermedius +
H. influenzae
|
1 (3.3)
|
S. intermedius +
Fusobacterium spp.
|
1 (3.3)
|
S. constellatus
|
11 (36.7)
|
S. constellatus only
|
8 (26.7)
|
S. constellatus +
E. coli
|
1 (3.3)
|
S. constellatus +
K. pneumoniae
|
1 (3.3)
|
S. constellatus +
Bacteroides spp. +
Peptostreptococcus spp.
|
1 (3.3)
|
S. anginosus
|
3 (10.0)
|
S. anginosus only
|
2 (6.7)
|
S. anginosus + Bacteroides spp.
|
1 (3.3)
|
The clinical features, laboratory features, treatment, and outcomes among the patients with single infections
Total
|
Pneumonia
|
Lung abscess
|
Bacterial pleurisy only
|
p-Value
|
|
---|---|---|---|---|---|
(
n = 24)
|
(
n = 16)
|
(
n = 5)
|
(
n = 3)
|
||
Age (y); mean ± SD
|
72.1 ± 11.6
|
74.8 ± 9.8
|
68.0 ± 15.4
|
65.0 ± 9.8
|
NS
|
Gender (male/female)
|
18/6
|
11/5
|
5/0
|
2/1
|
NS
|
BMI; mean ± SD
|
20.3 ± 4.4
|
19.6 ± 4.6
|
25.0 ± 3.5
|
19.6 ± 2.2
|
p = 0.032
**
|
Comorbidity diseases
|
23 (95.8)
|
16 (100)
|
4 (80.0)
|
3 (100)
|
NS
|
Neoplastic disease
|
7 (29.2)
|
4 (25.0)
|
2 (40.0)
|
1 (33.3)
|
NS
|
Cerebrovascular disease
|
9 (37.5)
|
7 (43.8)
|
1 (20.0)
|
1 (33.3)
|
NS
|
Chronic pulmonary disease
|
2 (8.3)
|
1 (6.3)
|
1 (20.0)
|
0 (0.0)
|
NS
|
Chronic cardiac disease
|
4 (16.7)
|
4 (25.0)
|
0 (0.0)
|
0 (0.0)
|
NS
|
Chronic liver disease
|
3 (12.5)
|
3 (18.8)
|
0 (0.0)
|
0 (0.0)
|
NS
|
Chronic renal disease
|
4 (16.7)
|
2 (12.5)
|
0 (0.0)
|
2 (66.7)
|
NS
|
Diabetes mellitus
|
6 (25.0)
|
4 (25.0)
|
0 (0.0)
|
2 (66.7)
|
NS
|
Smoking history
|
10 (41.7)
|
7 (43.8)
|
3 (60.0)
|
0 (0.0)
|
NS
|
Alcohol
|
6 (25.0)
|
5 (31.3)
|
1 (20.0)
|
0 (0.0)
|
NS
|
The days from symptom onset to consultation (days)
|
16.0 ± 19.6
|
9.0 ± 9.3
|
38.6 ± 30.8
|
16.0 ± 14.8
|
p = 0.031
*
|
Symptoms at presentation
|
|||||
Fever
|
19 (79.2)
|
13 (81.3)
|
4 (80.0)
|
2 (66.7)
|
NS
|
Cough
|
12 (50.0)
|
7 (43.8)
|
4 (80.0)
|
1 (33.3)
|
NS
|
Sputum
|
12 (50.0)
|
7 (43.8)
|
4 (80.0)
|
1 (33.3)
|
NS
|
Blood sputum
|
2 (8.3)
|
0 (0.0)
|
1 (20.0)
|
1 (33.3)
|
NS
|
Chest pain
|
12 (50.0)
|
9 (56.3)
|
1 (20.0)
|
2 (66.7)
|
NS
|
Disturbance of consciousness
|
3 (12.5)
|
3 (18.8)
|
0 (0.0)
|
0 (0.0)
|
NS
|
Previous antibiotic treatment
|
7 (29.2)
|
6 (37.5)
|
0 (0.0)
|
1 (33.3)
|
NS
|
Clinical parameter
|
|||||
Body temperature (°C)
|
37.8 ± 0.80
|
37.9 ± 0.81
|
37.5 ± 0.97
|
37.8 ± 0.59
|
NS
|
Systolic blood pressure (mmHg)
|
120.0 ± 22.2
|
117.8 ± 22.4
|
116.4 ± 19.3
|
135.3 ± 27.2
|
NS
|
Heart rate (beats/min)
|
100.6 ± 15.1
|
102.7 ± 16.7
|
93.6 ± 13.4
|
101.0 ± 3.6
|
NS
|
Respiratory rate (/min)
|
23.5 ± 6.1
|
25.0 ± 5.5
|
17.3 ± 5.1
|
27.0 ± 4.2
|
p = 0.029
*
|
Hypoxia (SpO
2 ≤ 90 %)
|
15 (62.5)
|
12 (75.0)
|
1 (20.0)
|
2 (66.7)
|
p = 0.047
*
|
Laboratory findings
|
|||||
White blood cell counts (/μL)
|
16,763 ± 9412
|
18,869 ± 9532
|
10,080 ± 2906
|
16,667 ± 13,164
|
p = 0.014
*
|
C-reactive protein (mg/dL)
|
18.2 ± 10.5
|
19.2 ± 11.0
|
11.7 ± 7.1
|
24.1 ± 9.6
|
NS
|
Albumin (g/dL)
|
2.5 ± 0.6
|
2.5 ± 0.7
|
2.7 ± 0.7
|
2.2 ± 0.4
|
NS
|
Pleural effusion
|
19 (79.2)
|
14 (87.5)
|
2 (40.0)
|
3 (100)
|
NS
|
Complicated pleural effusion
|
9 (37.5)
|
6 (37.5)
|
1 (20.0)
|
2 (66.7)
|
NS
|
Empyema
|
9 (37.5)
|
8 (50.0)
|
0 (0.0)
|
1 (33.3)
|
NS
|
Cultured bacteria
|
|||||
S. intermedius
|
14 (58.3)
|
11 (68.8)
|
3 (60.0)
|
0 (0.0)
|
NS
|
S. constellatus
|
8 (33.3)
|
4 (25.0)
|
2 (40.0)
|
2 (66.7)
|
NS
|
S. anginosus
|
2 (8.3)
|
1 (6.3)
|
0 (0.0)
|
1 (33.3)
|
NS
|
Pneumonia severity index
|
125.2 ± 37.3
|
128.1 ± 37.8
|
123.6 ± 48.6
|
112.0 ± 16.5
|
NS
|
Total
|
Pneumonia
|
Lung abscess
|
Bacterial pleurisy only
|
p-Value
|
|
---|---|---|---|---|---|
(
n = 24)
|
(
n = 16)
|
(
n = 5)
|
(
n = 3)
|
||
Monotherapy
|
20 (83.3)
|
12 (75.0)
|
5 (100)
|
3 (100)
|
NS
|
Penicillin/beta-lactamase inhibitors
|
1 (4.2)
|
1 (6.3)
|
0 (0.0)
|
0 (0.0)
|
NS
|
Carbapenem
|
17 (70.8)
|
10 (62.5)
|
4 (80.0)
|
3 (100)
|
NS
|
Linezolid
|
1 (4.2)
|
0 (0.0)
|
1 (20.0)
|
0 (0.0)
|
NS
|
Macrolide
|
1 (4.2)
|
1 (6.3)
|
0 (0.0)
|
0 (0.0)
|
NS
|
Combination therapy
|
4 (16.7)
|
4 (25.0)
|
0 (0.0)
|
0 (0.0)
|
NS
|
4th-cephem + Clindamycin
|
1 (4.2)
|
1 (6.3)
|
0 (0.0)
|
0 (0.0)
|
NS
|
Carbapenem + Clindamycin
|
2 (8.3)
|
2 (12.5)
|
0 (0.0)
|
0 (0.0)
|
NS
|
Fluoroquinolone + Clindamycin
|
1 (4.2)
|
1 (6.3)
|
0 (0.0)
|
0 (0.0)
|
NS
|
Additional treatment
|
16 (66.7)
|
12 (75.0)
|
1 (20.0)
|
3 (100)
|
NS
|
Only drainage
|
4 (16.7)
|
2 (12.5)
|
1 (20.0)
|
1 (33.3)
|
NS
|
Drainage + lung decortication
|
12 (50.0)
|
10 (62.5)
|
0 (0.0)
|
2 (66.7)
|
NS
|
Length of stay (days)
|
29.3 ± 19.7
|
31.4 ± 20.9
|
28.6 ± 21.0
|
19.0 ± 9.5
|
NS
|
ICU admission
|
6 (25.0)
|
6 (37.5)
|
0 (0.0)
|
0 (0.0)
|
NS
|
In hospital mortality
|
2 (8.3)
|
2 (12.5)
|
0 (0.0)
|
0 (0.0)
|
NS
|